Europe Joint Pain Injection Market

Market Introduction

The Europe joint pain injection market is

a

highly fragmented market with the presence of considerable regional and local players providing numerous solutions for companies investing in the market arena. Hyaluronic acid injections offered by companies are usually administered for treating sports injuries, as they aid in pain relief, reduce inflammation, and improve joint function. Corticosteroids are also used to treat sports-related injuries. Sports injuries are caused due to direct impact, or the application of force that is larger than the body part can withstand. The most common sport injuries are sprains, strains, joint injuries, and bruises. Developments by the market players in the region is further boosting the growth of the market. In August 2020, Lupin Limited (Lupin) and Mylan N.V. launched of Nepexto, biosimilar etanercept, in the German market which is indicated for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondylarthritis, plaque psoriasis and chronic severe plaque psoriasis. Such product launches of drugs are likely to favor the growth of the market.

Several European countries witnessed an unprecedented rise in the number of COVID-19 cases, which led to the discontinuation of several business operations and manufacturing activities of various healthcare products, including joint pain injections, which negatively impacted the joint pain injection market. Also, the pandemic has halted the adoption of new medical device policy and delayed clinical trials and disrupted processes. Two consecutive waves of coronavirus had devastating impact on economic activities in the Europe. Implementation of social distancing and lockdown policies led to closing of orthopedic hospitals and patient visits for elective orthopedic surgeries. This factor negatively impacted the adoption of joint pain injection. In addition, disrupted supply chains, extended lockdowns, and cancelling of orthopedic medical procedures have also negativity affected the growth of the joint pain injection market. The hospitals in the region are cancelling other surgical procedures to keep healthcare facilities free for COVID-19 patients. Moreover, increasing COVID-19 infection in healthcare workers is leading to shortage of staff. These factors are negatively impacting the growth of the joint pain injection market.

Europe Joint Pain Injection Strategic Insights

Strategic insights for the Europe Joint Pain Injection provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Europe Joint Pain Injection Report Scope

Europe Joint Pain Injection Regional Insights

The geographic scope of the Europe Joint Pain Injection refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Market Overview and Dynamics

The joint pain injection market in Europe is expected to grow from US$ 595.20 million in 2021 to US$ 1,035.54 million by 2028; it is estimated to grow at a CAGR of 8.2% from 2021 to 2028. Countries in Europe are emerging as attractive outsourcing locations for pharmaceuticals and biopharmaceuticals industries. Flourishing domestic pharmaceutical market and increasing number of pipeline drugs are further opening new avenues for the contract manufacturers as well as generic drug manufacturing in the region. Additionally, to meet the growing demand, many contract-based organizations are expanding their manufacturing capabilities. Thus, the emerging markets hold high potential and huge revenue generation opportunities for the pharmaceutical manufacturing companies. Increasing prevalence of joint pain is driving the joint pain injection market. According to the results of survey on “Les Français et les Rhumatismes” (Rheumatic Diseases and the French), conducted by Inserm and “Ensemble Contre les Rhumatismes” (Together Against Rheumatic Diseases), 93% of French people report having suffered from joint pain. Furthermore, it has also mentioned that 12-13 million French people have suffered from rheumatic diseases that includes 9 -10 million people suffering from osteoarthritis, around 6,00,000 from chronic inflammatory rheumatic diseases and nearly 4,000 children suffer from idiopathic juvenile arthritis. Thus, growing prevalence of joint diseases is likely to drive the market growth during the forecast period.

Key Market Segments

Based on drugs, the hyaluronic acid segment accounted for the largest share of the Europe joint pain injection market in 2020. Based on joint type, the knee segment accounted for the largest share of the Europe joint pain injection market in 2020. Based on distribution channel, the hospitals pharmacies segment accounted for the largest share of the Europe joint pain injection market in 2020.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the Europe joint pain injection market are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report include Chugai Pharmaceutical Co., Ltd.; Bioventus Inc.; Fidia Pharma USA Inc.; Seikagaku Corporation; Ferring B.V.; Sanofi; Anika Therapeutics, Inc; and Teva Pharmaceutical Industries Ltd.

Reasons to buy report

• To understand the Europe joint pain injection market landscape and identify market segments that are most likely to guarantee a strong return
• Stay ahead of the race by comprehending the ever-changing competitive landscape for Europe joint pain injection market
• Efficiently plan M&A and partnership deals in Europe joint pain injection market by identifying market segments with the most promising probable sales
• Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Europe joint pain injection market
• Obtain market revenue forecast for market by various segments from 2020-2028 in Europe region.

Europe Joint Pain Injection Market Segmentation

Europe Joint Pain Injection Market -B

y Drugs

• Hyaluronic Acid
• Corticosteroid
• Others

Europe Joint Pain Injection Market -By Joint Type

• Knee
• Foot and Ankle
• Shoulder and Elbow
• Hip
• Others

Europe Joint Pain Injection Market -By Distribution Channel

• Retail Pharmacies
• Hospitals Pharmacies
• Others

Europe Joint Pain Injection Market – By Country

• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe

Europe Joint Pain Injection Market – Company Profiles

• Chugai Pharmaceutical Co., Ltd.
• Bioventus Inc.
• Fidia Pharma USA Inc.
• Seikagaku Corporation
• Ferring B.V.
• Sanofi
• Anika Therapeutics, Inc.
• Teva Pharmaceutical Industries Ltd.